YIV-201

About Yiviva

Yiviva is pioneering a novel approach to drug development by leveraging botanical formulations and systems biology to create multi-targeted therapies for complex chronic diseases and oncology. The company's lead program, YIV-906 (also known as PHY906), is a repurposed ancient herbal formula in Phase 2b trials for hepatocellular carcinoma and has shown promise in mitigating chemotherapy side effects. Founded by systems biology experts from Yale University, Yiviva combines modern computational biology with traditional medicine insights. The company is privately held, backed by venture capital, and strategically positioned to address large markets with high unmet need through a potentially safer and more efficacious therapeutic paradigm.

Therapeutic Areas